The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory disorders, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. According to the data provided by the WHO, more than 3 million people die annually from COPD. Asthma, on the other hand, is more common in pediatric population. Asthma alone results in more than 30% of pediatric hospitalizations. Moreover, it is responsible for around 180,000 annual deaths worldwide.
Respiratory Disorders are Amongst the Most Prevalent Global Diseases
Evaluation of opinions expressed across social media platforms, recent publications and by KOLs highlights significant unmet needs across these diseases.
Current Research Initiatives are Focused on a Number of Unmet Needs
To overcome these unmet needs, stakeholders must focus on development of therapies / solutions to address issues related to medication adherence and disease diagnosis.
Novel Targets are Being Explored Across Asthma, COPD and Cystic Fibrosis
Innovation in this segment is presently concentrated on exploring unique targets and developing personalized therapies for patients with moderate to severe form of disease
Both Big and Small Pharma are Actively Driving the Research Effortsin the Respiratory Disorders Market
The efforts are being jointly led by large and small-mid size pharma companies aiming to occupy a relatively larger share of this highly lucrative market
Many Companies, with Compelling Brand Positioning, Have Recently Emerged
Specific companies, which are developing novel solutions and have a relatively stronger brand positioning, are expected to transform the treatment options in the mid-long term
Smart Inhalers Are Also Gaining Rapid Popularity
With the growing traction towards digital solutions to overcome specific patient needs, smart inhalers are also likely to offer significant opportunities
The Overall Opportunity for Novel Drug Classes is Expected to Steadily Grow
Driven by encouraging clinical trial results and increasing adoption of these novel therapies, the respiratory disorders market is poised to grow at a rapid pace
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.